Moneycontrol
    Moneycontrol PRO
    LAMF
    LAMF

    Jump to

    • There is high pricing pressure on manufacturers: DRL

    • FM's universal healthcare proposal a step in right direction: DRL

    • Hope to resolve Srikakulam with US FDA soon, says DRL

    • TCS biggest wealth creator in 2012-17, Ajanta Pharma the fastest: Wealth Creation Study

    • Profits from Copaxone generics to help strengthen balance sheet, expansion: Natco CEO

    • New draft pharma policy will reduce risks like generalisation of mkt: JM Financial

    • Preparing for GST implementation for past few months: DRL's Chakraborty

    • Expect to see 18-20% growth for FY18: TCI Express

    • Govt needs to be a strong enabler in pharma sector: Experts

    • Expect US FDA approvals to pick going forward: Dr Reddy's

    • Q4 to be lean qtr for US biz due to delayed launches: Dr Reddy's

    • No scope of US intervention in Indian pharma cos: Wockhardt

    • New launches in H2FY17 will boost growth: Dr Reddy's

    • Indian assets doing well; hopeful of few launches in US: DRL

    • Lupin to see approvals after US FDA gives clean chit: Macquarie

    • Hope to commercialise 4 products acquired from Teva by FY18: DRL

    • After DRL-Teva, expect more M&A action in pharma: Prabhudas

    • US FDA issues shouldn't be overbearing factor for pharma: Citi

    • New launches to drive growth in second quarter: Dr Reddy's

    • Regulatory issues discussed in Feb meet with US, Europe: DRL

    • Indian pharma cos need to step-up safeguards at plants: Handa

    • 20% of Cipla FY17 revenues to come from US: Chirag Talati

    • Board to consider buyback of equity shares on Feb 17: Dr Reddy's

    • See huge opportunity in Venezuela; US supply not restricted: DRL

    • Pharma cos capable of resolving FDA concern in 12-15 months:IIFL

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347